Indian Patent Office Rejects AbbVie's Venetoclax Patent Application, Opening Door for Generic Competition
核心洞察
The Indian Patent Office (搜索) rejected AbbVie (搜索)'s patent application for its cancer (搜索) drug Venetoclax, citing lack of inventive steps and violation of Section 3(d) of the Indian Patent Act.
The decision affects treatment for blood cancers (搜索) including chronic lymphocytic leukemia (搜索) and acute myeloid leukemia (搜索), potentially enabling affordable generic versions to enter the Indian market.
Seven parties filed sustained opposition to the patent application between 2018 and 2025, with the patent office ruling the claimed invention was "obvious" and failed to demonstrate enhanced therapeutic efficacy.
The Indian Patent Office (搜索) (IPO) has rejected a patent application filed by multinational pharmaceutical company AbbVie (搜索) for its cancer (搜索) drug Venetoclax, citing lack of inventive steps and potential patent evergreening. The decision could pave the way for lower-cost generic versions of the blood cancer treatment to enter the Indian market.
Patent Rejection Details
The IPO's Delhi office declined to grant the patent for Venetoclax, which is used in the treatment of certain blood cancers (搜索), including chronic lymphocytic leukemia (搜索) and acute myeloid leukemia (搜索). AbbVie (搜索) markets the drug in India under the brand name Venclexta, and the company holds another patent related to the drug's composition that is currently facing legal challenges in court.
The patent application faced sustained opposition at the pre-grant stage, with seven parties filing challenges between 2018 and 2025. The patent office determined that the claimed invention was "obvious" and lacked an inventive step, constituting a violation of Section 3(d) of the Indian Patent Act.
Legal Framework and Precedent
Section 3(d) of the Indian Patent Act restricts patents on new forms or derivatives of known substances unless they demonstrate a significant enhancement in therapeutic efficacy. This provision is specifically designed to prevent "evergreening" of pharmaceutical patents, where companies seek to extend patent protection through minor modifications.
The same legal provision was applied in 2013 when Swiss drugmaker Novartis lost its patent claim on its cancer (搜索) drug Glivec, establishing an important precedent for pharmaceutical patent challenges in India.
Patent Office Findings
In its order, the patent office stated that the "claims of complete specification is not patentable under the Act, does not describe the invention," and added that it offered "no enhancement in therapeutic efficiency," constituting a case of evergreening.
The patent office specifically noted that the applicants failed to provide data demonstrating improved therapeutic efficacy of the claimed compounds over those disclosed in prior art. "In absence of any biological data for all claimed compounds in the present specification, it cannot be decided whether the claims actually have the claimed anti-cancer (搜索) activity or not," the order stated.
The ruling concluded that the applicants "completely failed to establish any pharmacological activity and/or therapeutic efficacy for all the millions of claimed compounds."
Market Implications
Legal experts indicate that if AbbVie (搜索) does not challenge this decision, it could enable the entry of affordable generic versions of Venetoclax in the Indian market. This development could significantly benefit patients requiring treatment for blood cancers (搜索), as generic versions typically offer substantial cost savings compared to branded medications.
The rejection represents another significant case where India's patent law provisions have been successfully applied to prevent what regulators view as attempts to extend patent protection without demonstrating meaningful therapeutic improvements.